It may have started from a low base, but the Indian biotech industry is hurtling past the global growth rate. And overseas companies are anxious to get in on the action.
A team of researchers from ETH-Zürich is looking for investment for their spin-off company, XpresSys, to commercialise novel protein expression technology. The technology has the potential to revolutionise screening process for new drugs.
A spin off from ETH-Zürich has devised a new generation of detection equipment that could help in the fight against terrorism. The company is now seeking investment and possible partnerships to take the technology to a commercial level.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.